Rivaroxaban versus Enoxaparin in Patients with Radial Artery Occlusion after Transradial Coronary Catheterization:A Pilot Randomization Trial
- Author:
Mohsen MAADANI
1
;
Soudabeh Shafiee ARDESTANI
;
Farnaz RAFIEE
;
Kiara REZAEI-KALANTARI
;
Parham RABIEE
;
Yasmin Mohtasham KIA
;
Ali ZAHEDMEHR
;
Bahram MOHEBBI
;
Armin ELAHIFAR
;
Ehsan KHALILIPUR
;
Ata FIROUZI
;
Parham SADEGHIPOUR
Author Information
- Publication Type:Rapid Communication
- From:Vascular Specialist International 2025;41(1):2-
- CountryRepublic of Korea
- Language:English
- Abstract: The radial artery is currently the main vascular access site for cardiac catheterization. Radial artery occlusion (RAO), although a relatively silent complication, raises concerns because of its potential impact on future procedures. This pilot randomized controlled trial compared the efficacy and safety of two anticoagulation regimens—subcutaneous enoxaparin and oral rivaroxaban—in resolving symptomatic ultrasound-confirmed RAO in 40 patients (median age 55 years [interquartile range, 48-64], including 26 female patients [70.3%]) who underwent diagnostic cardiac catheterization without requiring dual antiplatelet therapy. Thirty-seven patients completed the 28-day ultrasound-based follow-up, demonstrating comparable complete or partial resolution rates between rivaroxaban (16 of 20 patients [80.0%]) and enoxaparin (14 of 17 patients [82.3%]), with an odds ratio of 0.85 (95% confidence interval: 0.16 to 4.50). No major bleeding events occurred during the 28-day follow-up period. While rivaroxaban shows potential in resolving RAO, larger studies are necessary to validate these findings and evaluate the long-term outcomes.
